Tom De Bruyn (Tom de Bruyn)

Publication Activity (10 Years)

Years Active: 2019-2024
Publications (10 Years): 8

Top Topics

Multiple Myeloma

Bioinformatics Analysis

Estrogen Receptor

Top Venues

Drug metabolism and disposition: the biological fate of chemicals

Journal of medicinal chemistry

Biopharmaceutics & drug disposition

Cancer research communications

This page only lists publications with an associated author ORCID identifier.

Publications

Marie-Gabrielle Braun, Avi Ashkenazi, Ramsay E Beveridge, Georgette Castanedo, Heidi Ackerly Wallweber, Maureen H Beresini, Kevin R Clark, Tom De Bruyn, Liqiang Fu, Paul Gibbons, Fan Jiang, Susan Kaufman, David Kan, James R Kiefer, Jean-Philippe Leclerc, Alexandre Lemire, Cuong Ly, Ehud Segal, Jessica Sims, Weiru Wang, Wentao Wei, Liang Zhao, Jacob B Schwarz, Joachim Rudolph
Discovery of Potent, Selective, and Orally Available IRE1α Inhibitors Demonstrating Comparable PD Modulation to IRE1 Knockdown in a Multiple Myeloma Model. Journal of medicinal chemistry (2024)
Smita Kshirsagar, Ya-Chi Chen, Jiajie Yu, Mary R Gates, Sonoko Kawakatsu, S Cyrus Khojasteh, Shuguang Ma, Luna Musib, Vikram Malhi, Uyi Osaghae, Jing Wang, Sungjoon Cho, Yang Tang, Donglu Zhang, Weiping Zhao, Tom De Bruyn
Mass Balance, Metabolic Pathways, Absolute Bioavailability, And Pharmacokinetics of Giredestrant In Healthy Subjects. Drug metabolism and disposition: the biological fate of chemicals (2024)
Marie-Gabrielle Braun, Avi Ashkenazi, Ramsay E Beveridge, Georgette Castanedo, Heidi Ackerly Wallweber, Maureen H Beresini, Kevin R Clark, Tom De Bruyn, Liqiang Fu, Paul Gibbons, Fan Jiang, Susan Kaufman, David Kan, James R Kiefer, Jean-Philippe Leclerc, Alexandre Lemire, Cuong Ly, Ehud Segal, Jessica Sims, Weiru Wang, Wentao Wei, Liang Zhao, Jacob B Schwarz, Joachim Rudolph
Discovery of Potent, Selective, and Orally Available IRE1α Inhibitors Demonstrating Comparable PD Modulation to IRE1 Knockdown in a Multiple Myeloma Model. Journal of medicinal chemistry 67 (11) (2024)
Smita Kshirsagar, Ya-Chi Chen, Jiajie Yu, Mary R Gates, Sonoko Kawakatsu, S Cyrus Khojasteh, Shuguang Ma, Luna Musib, Vikram Malhi, Uyi Osaghae, Jing Wang, Sungjoon Cho, Yang Thomas Tang, Donglu Zhang, Weiping Zhao, Tom De Bruyn
Mass Balance, Metabolic Pathways, Absolute Bioavailability, and Pharmacokinetics of Giredestrant in Healthy Subjects. Drug metabolism and disposition: the biological fate of chemicals 52 (8) (2024)
Vikram Malhi, Priya Agarwal, Mary R Gates, Lichuan Liu, Jianshuang Wang, Tom De Bruyn, Scott Lam, Jennifer Eng-Wong, Pablo Perez-Moreno, Ya-Chi Chen, Jiajie Yu
Optimizing Early-Stage Clinical Pharmacology Evaluation to Accelerate Clinical Development of Giredestrant in Advanced Breast Cancer. Cancer research communications (2023)
Jialin Mao, Fang Ma, Jesse Yu, Tom De Bruyn, Miaoran Ning, Christine Bowman, Yuan Chen
Shared learning from a physiologically based pharmacokinetic modeling strategy for human pharmacokinetics prediction through retrospective analysis of Genentech compounds. Biopharmaceutics & drug disposition (2023)
Anjani Ganti, Sijia Yu, Danielle Sharpnack, Ellen Ingalla, Tom De Bruyn
Physiologically-based pharmacokinetic/pharmacodynamic modeling to predict tumor growth inhibition and the efficacious dose of selective estrogen receptor degraders in humans. Biopharmaceutics & drug disposition (2023)
Paul Oranje, Robin Gouka, Lindsey Burggraaff, Mario Vermeer, Clément Chalet, Guus Duchateau, Pieter van der Pijl, Marian Geldof, Niels de Roo, Fenja Clauwaert, Toon Vanpaeschen, Johan Nicolai, Tom De Bruyn, Pieter Annaert, Adriaan P IJzerman, Gerard van Westen
Novel natural and synthetic inhibitors of solute carriers SGLT1 and SGLT2. Pharmacology research & perspectives 7 (4) (2019)